Skip to main content

Table 1 Characteristics of included patients. Percentages are rounded and are for guidance only

From: Does the introduction of an infliximab biosimilar always result in savings for hospitals? A descriptive study using real-world data

Cohort

Sex n tot. (%F)

Median Age years (IQR)

Disease category n (%)

GAS

IMM

RHE

Inpatients and outpatients

258 (54)

42 (28)

114 (44)

60 (23)

84 (33)

Started OI and maintained OI

78 (52)

45 (30)

31 (40)

28 (36)

19 (25)

Started CT-P13 and maintained CT-P13

43 (51)

36 (25)

17 (40)

14 (33)

12 (28)

Started OI and discontinued OI

19 (79)

34 (25)

11 (58)

1 (5)

7 (37)

Started CT-P13 and discontinued CT-P13

32 (56)

32 (19)

18 (56)

6 (19)

8 (25)

Switched from OI to CT-P13 and maintained CT-P13

54 (46)

48 (32)

25 (46)

6 (11)

23 (43)

Switched from OI to CT-P13 and discontinued CT-P13

16 (50)

39 (28)

7 (44)

2 (13)

7 (44)

Switched from OI to CT-P13 and switched back to OI

16 (75)

54 (13)

5 (31)

3 (19)

8 (50)

  1. %F percentage of female patients, GAS Gastroenterology, IMM Immunoallergology, IQR Inter-quartile range, OI Originator infliximab, tot total number of patients